UNLIMITED
Addressing Age-Related Comorbidities Among People With HIV: Hear insights from Dr. Daniel Kuritzkes and Dr. Christian Ramers on preventing ART-associated bone loss, reducing cardiovascular disease risk, and managing HIV-associated neurocognitive disorders in this case-based discussion of comorbidity management and ART selection for aging patients with HIV. by CCO Infectious Disease PodcastUNLIMITED
An HIV Vaccine: An Unfulfilled Promise—Episode 2, Learning Through Failing
UNLIMITED
An HIV Vaccine: An Unfulfilled Promise—Episode 2, Learning Through Failing
ratings:
Length:
28 minutes
Released:
Jun 18, 2021
Format:
Podcast episode
Description
Produced in collaboration with the Global HIV Vaccine Enterprise at the International AIDS Society (IAS), this 4-episode podcast series features conversations between world-renowned guests in HIV vaccine development, HIV advocacy, and HIV policy to bust myths and address arguments for why an HIV vaccine is still needed and how we can continue working toward this ultimate game-changer for durable control of the HIV epidemic. In this episode, Dr. Susan Buchbinder and Mr. Jontraye Davis discuss what has been learned and built through the past 40 years of HIV vaccine research, including how HIV vaccine scientific advancements and infrastructure were critical to the success of developing a COVID-19 vaccine.Presenters:Susan Buchbinder, MDClinical ProfessorDepartments of Medicine, Epidemiology and BiostatisticsUniversity of California, San FranciscoDirector, Bridge HIVSan Francisco Department of Public HealthSan Francisco, California Jontraye Davis, MHA, PMD ProCommunity Program Manager FHI 360Adjunct InstructorNorth Carolina Central UniversityDurham, North CarolinaSpecial Commentator: Jerome H. Kim, MDDirector GeneralInternational Vaccine InstituteSeoul, South KoreaLink to full series:https://bit.ly/3ytytMYLink to the HIV unmuted series from IAS:https://bit.ly/3f5qC0dContent is part of a CME-certified educational program that is supported by independent educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp; and ViiV Healthcare.
Released:
Jun 18, 2021
Format:
Podcast episode
Titles in the series (100)
- 30 min listen